Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0OM5M
|
||||
| Former ID |
DIB006060
|
||||
| Drug Name |
Ro-48-1220
|
||||
| Indication | Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10:A00-B99] | Terminated | [1] | ||
| Company |
Roche Holding AG
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
S1(=O)(=O)[C@]([C@@H](N2[C@H]1CC2=O)C(=O)O)(/C=C\C#N)C
|
||||
| CAS Number |
CAS 180323-80-2
|
||||
| Target and Pathway | |||||
| Target(s) | Beta-lactamase | Target Info | Modulator | [2] | |
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004684) | ||||
| REF 2 | Comparative in vitro activity of apalcillin alone and combined with Ro 48-1220, a novel penam beta-lactamase inhibitor. Clin Microbiol Infect. 1995 Feb;1(2):86-100. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.